TIAA CREF Investment Management’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

TIAA CREF Investment Management’s Portfolio ONCT Stock Details ONCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-109	Closed	-$24K	–	3035
2018 Q3	$24K	Buy	+109	New	+$262K	﹤0.01%	3053
2014 Q2	–	Sell	-52	Closed	-$111K	–	3189
2014 Q1	$111K	Hold	52	–	–	﹤0.01%	3101
2013 Q4	$120K	Buy	52 +45	+643%	+$103K	﹤0.01%	3105
2013 Q3	$18K	Sell	7 -73	-91%	-$363K	﹤0.01%	3091
2013 Q2	$739K	Buy	+80	New	+$616K	﹤0.01%	2770

Other funds holding ONCT

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

TIAA CREF Investment Management's ONCT Position: Q4 2018 in Review

TIAA CREF Investment Management sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q4 2018, closing a stake of 109 shares — an estimated $24K sold.

TIAA CREF Investment Management first reported a position in ONCT in Q2 2013 and held it in 5 quarters. The position peaked at $739K in Q2 2013. 43 funds tracked by Wall St. Rank hold ONCT as of Q4 2018.

TIAA CREF Investment Management reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
TIAA CREF Investment Management sold 109 Oncternal Therapeutics, Inc. Common Stock shares in Q4 2018, an estimated $24K.
TIAA CREF Investment Management first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2013 and held it in 5 quarters.
TIAA CREF Investment Management's Oncternal Therapeutics, Inc. Common Stock position peaked at $739K in Q2 2013.
43 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q4 2018.

Based on TIAA CREF Investment Management's 13F filing for Q4 2018, filed 14 Feb 2019.